BTAI
BioXcel Therapeutics IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$35.20M
P/E Ratio
—
EPS
$-4.77
Beta
0.32
52W High
$8.08
52W Low
$1.01
50-Day MA
$1.15
200-Day MA
$1.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.
Fundamentals
| Revenue (TTM) | 680,000 |
| Gross Profit (TTM) | 247,000 |
| EBITDA | $-50.11M |
| Operating Margin | -4963.00% |
| Return on Equity | -1767.00% |
| Return on Assets | -86.80% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $-3.90 |
| Price-to-Book | 27.50 |
| Price-to-Sales (TTM) | 51.77 |
| EV/Revenue | 174.67 |
| EV/EBITDA | -0.76 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 22.60% |
| Shares Outstanding | $30.88M |
| Float | $26.36M |
| % Insiders | 3.65% |
| % Institutions | 18.72% |
Historical Volatility
HV 10-Day
71.41%
HV 20-Day
76.30%
HV 30-Day
66.96%
HV 60-Day
76.14%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($14.00 target)
3
Buy1
Strong SellMore HEALTHCARE Stocks
Data last updated: 6/13/2026